NCT05357898 is a Phase 1, PHASE2 clinical trial of SQZ-eAPC-HPV in Adult Solid Tumor, sponsored by SQZ Biotechnologies.

Who is sponsoring NCT05357898?

NCT05357898 is sponsored by SQZ Biotechnologies.

What drugs are being tested in NCT05357898?

Interventions in NCT05357898: SQZ-eAPC-HPV, Pembrolizumab.

What condition does NCT05357898 study?

NCT05357898 studies Adult Solid Tumor.

Is NCT05357898 still recruiting?

NCT05357898 is currently terminated. Last updated 23 February 2024.

Last reviewed 2024-02-23 · How we verify

NCT05357898

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated Phase 1, PHASE2 Last updated 23 February 2024

What this trial tests

Phase 1, PHASE2 trial testing SQZ-eAPC-HPV in Adult Solid Tumor in 20 participants. Terminated before completion.

Timeline

24 March 2022

Primary endpoint
27 November 2023

27 November 2023

Quick facts

Lead sponsor	SQZ Biotechnologies
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	24 March 2022
Primary completion	27 November 2023
Estimated completion	27 November 2023
Sites	9 locations across United States

Drugs / interventions tested

SQZ-eAPC-HPV — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Adult Solid Tumor — all drugs for Adult Solid Tumor →

Sponsor

SQZ Biotechnologies — full company profile →

Who can join

18 and older, any sex, with Adult Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV as monotherapy and in combination with pembrolizumab in patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. The study includes patients with head and neck, cervical, anal, vulvar, or penile cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.
Ye J, Zheng L, He Y, Qi X. · · 2023 · cited 27× · PMID 37719443 · DOI 10.1002/mco2.368
PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications.
Aguayo F, Perez-Dominguez F, Osorio JC, Oliva C, et al · · 2023 · cited 27× · PMID 37237486 · DOI 10.3390/biology12050672
Messenger RNA-Based Therapeutics and Vaccines: What's beyond COVID-19?
Li D, Liu C, Li Y, Tenchov R, et al · · 2023 · cited 22× · PMID 37470024 · DOI 10.1021/acsptsci.3c00047
Application of mRNA Technology in Cancer Therapeutics.
Eralp Y. · · 2022 · cited 13× · PMID 36016150 · DOI 10.3390/vaccines10081262
Personalized nanovaccines for treating solid cancer metastases.
Feng T, Hu J, Wen J, Qian Z, et al · · 2024 · cited 7× · PMID 39609851 · DOI 10.1186/s13045-024-01628-4
Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.
Hughes RT, Gebeyehu RR, Kalada JM, Lycan TW, et al · · 2023 · cited 6× · PMID 37199326 · DOI 10.2217/fon-2022-1146
Microfluidic cell squeeze-based vaccine comes into clinical investigation.
Wang S, Yang Y, Zha Y, Li N. · · 2023 · cited 4× · PMID 37142615 · DOI 10.1038/s41541-023-00641-x
Human Papillomavirus-Directed Therapeutics for Human Papillomavirus-Associated Oropharyngeal Cancer.
Campbell JS, Pai SI. · · 2022 · cited 4× · PMID 36165730 · DOI 10.1097/ppo.0000000000000621

Verify or expand the search:

Other recruiting trials for Adult Solid Tumor

Currently open trials in the same condition.

NCT07246863 — Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic N · Phase 2 · recruiting
NCT07098988 — Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NS · Phase 2 · recruiting
NCT06059547 — Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer · Phase 2 · active not recruiting
NCT02568267 — Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), · Phase 2 · active not recruiting

Other SQZ Biotechnologies trials

Trials by the same sponsor.

NCT04892043 — Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors · Phase 1 · terminated
NCT04084951 — Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05357898 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SQZ Biotechnologies
Last refreshed: 23 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05357898.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing